Scilex Approved A Resolution To Authorize Management To Explore Ways In Which To Maximize Value Of Semnur Pharmaceuticals And SP-102

6/17/24 3:38:07 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $SCLX alert in real time by email

On June 17, 2024, the Board of Directors of Scilex Holding Company (the "Company") approved a resolution to authorize management to explore ways in which to maximize the value of Semnur Pharmaceuticals, Inc. ("Semnur"), the Company's wholly owned subsidiary, and SP-102 (SEMDEXA™), the product candidate held by Semnur, for the Company and its stockholders, including by way of conducting a spin-off, merger, dividend, reclassification or other similar transaction.

Get the next $SCLX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SCLX

Date	Price Target	Rating	Analyst
10/16/2024	$14.00	Buy	Alliance Global Partners
6/13/2024	$13.00	Buy	Rodman & Renshaw
10/16/2023	$4.00	Buy	B. Riley Securities
10/13/2023	$4.00	Buy	B. Riley Securities
10/9/2023	$12.00	Buy	H.C. Wainwright

More analyst ratings

Scilex Selling Shareholder Files For Sale Of Up To 3.5M Shares
7/18/24 4:24:02 PM ET
$SCLX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Scilex Announces Collaboration To Leverage ACEA Therapeutics' R&D Expertise To Support The Expansion Of ZTlido Program In Ex-U.S. And Potentially Provide Additional Access To Patients In Certain Key Markets In Far East Region
ACEA Therapeutics ("ACEA") will serve as exclusive territories distributor in Greater China, including mainland China, Taiwan, Hong Kong and Macau, with potential minimum purchase commitment for ZTlido once approved locally in the region.ACEA to immediately start the process to explore potential commercialization of ZTlido®, with the opportunity to distribute with partners across Greater China and further expand the relationship to include other products in Scilex's non-opioid pain portfolio.PALO ALTO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or the "Company"))))), an innovative revenue-generating company focused on acquiring, developing and com
7/17/24 9:10:57 AM ET
$SCLX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Non-Opioid Pain Therapy-Focused Semnur Pharmaceuticals Strikes $2B SPAC Deal For NASDAQ Debut
Semnur Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company (NASDAQ:SCLX), and Denali Capital Acquisition Corp. (NASDAQ:DECA), a special purpose acquisition company, signed a letter of intent for a proposed business combination. The deal provides for a pre-transaction equity value of Semnur up to $2 billion, with expected gross proceeds of up to $40 million depending on the number of SPAC shares redeemed before the business combination is completed. Semnur is a clinical late-stage specialty pharmaceutical company focused on developing and commercializing novel non-opioid pain therapies. Semnur’s lead program, SP-102 (SEMDEXA), is the first non-opioid novel injectab
7/3/24 10:51:16 AM ET
$DECA
$SCLX
Blank Checks
Finance
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$SCLX
Financials

Live finance-specific insights

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali
As previously announced, Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC")) entered into an agreement and plan of merger, dated as of August 30, 2024 (the "Merger Agreement"), related to the proposed business combination (the "Business Combination") of Denali and Semnur, which provides for a pre-transaction equity value of Semnur of $2.5 billion. The closing of the Business Combination is expected to occur by the first quarter of 2025. As previously disclosed, the Board of Directors of Scilex declared a stock dividend consisting of an aggregate of 5,000,000 shares of Series 1 Mandator
11/6/24 12:24:36 PM ET
$DECA
$SCLX
Blank Checks
Finance
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock
Scilex management is determined to enhance its stockholders' value and protect their stockholder rights, and is taking steps to combat manipulative and naked short selling practices in Scilex common stock.Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of Scilex. Such record date may be changed by Scilex's board of directors for any reason at any time prior to the actual payment of such dividend of Scilex preferred stock. No payment date has been set for the payment of such dividend and such payment is conditioned upon the Scilex board of director
10/29/24 6:00:00 AM ET
$SCLX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary
Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 (the "Record Date") for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of Scilex.Based on independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™), the product candidate held by Semnur Pharmaceuticals, Inc. ("Semnur") is estimated to have peak sales potential projected to be $3.6 billion annually in the 5th year post launch of SP-102.Scilex previously announced that it anticipates the filing of a Registration Statement on Form S-4 (the "Registration Statement") with
10/28/24 6:00:00 AM ET
$DECA
$SCLX
Blank Checks
Finance
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$SCLX
Press Releases

Fastest customizable press release news feed in the world

Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024
PALO ALTO, Calif. , Nov. 15, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced presentation of data at the 2024 American College of Rheumatology Convergence conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024. Title: Prophylaxis of Gout Flares in Patients with Renal Impairment: Dosing Adjustments with Colchicine Oral Solution Informed by a Pharmacokinetic Model
11/15/24 9:00:00 AM ET
$SCLX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
NEW YORK, NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $15,063.74 to fund the one-month extension from November 11, 2024, to December 11, 2024. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing o
11/11/24 5:01:32 PM ET
$DECA
$SCLX
Blank Checks
Finance
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali
As previously announced, Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC")) entered into an agreement and plan of merger, dated as of August 30, 2024 (the "Merger Agreement"), related to the proposed business combination (the "Business Combination") of Denali and Semnur, which provides for a pre-transaction equity value of Semnur of $2.5 billion. The closing of the Business Combination is expected to occur by the first quarter of 2025. As previously disclosed, the Board of Directors of Scilex declared a stock dividend consisting of an aggregate of 5,000,000 shares of Series 1 Mandator
11/6/24 12:24:36 PM ET
$DECA
$SCLX
Blank Checks
Finance
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Scilex Approved A Resolution To Authorize Management To Explore Ways In Which To Maximize Value Of Semnur Pharmaceuticals And SP-102

Chat with this insight

Recent Analyst Ratings for $SCLX

$SCLX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Executive Chairperson Ji Henry bought $8,351 worth of shares (8,888 units at $0.94), increasing direct ownership by 3% to 320,161 units (SEC Form 4)

Officer Shah Jaisim bought $31,670 worth of shares (32,000 units at $0.99), increasing direct ownership by 41% to 109,333 units (SEC Form 4)

Director Followwill Dorman bought $990 worth of shares (1,000 units at $0.99), increasing direct ownership by 77% to 2,300 units (SEC Form 4)

$SCLX Leadership Updates

Live Leadership Updates

Scilex Holding Company Strengthens Board of Directors with Appointment of Highly Accomplished Leader in Interventional and Multidisciplinary Spine, Musculoskeletal and Orthopedic Care, Annu Navani, M.D.

Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates

$SCLX SEC Filings

SEC Form 424B3 filed by Scilex Holding Company

SEC Form 424B3 filed by Scilex Holding Company

SEC Form 8-K filed by Scilex Holding Company

$SCLX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Executive Chairperson Ji Henry bought $8,351 worth of shares (8,888 units at $0.94), increasing direct ownership by 3% to 320,161 units (SEC Form 4)

Officer Shah Jaisim bought $31,670 worth of shares (32,000 units at $0.99), increasing direct ownership by 41% to 109,333 units (SEC Form 4)

Director Followwill Dorman bought $990 worth of shares (1,000 units at $0.99), increasing direct ownership by 77% to 2,300 units (SEC Form 4)

$SCLX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Alliance Global Partners initiated coverage on Scilex Holding with a new price target

Rodman & Renshaw initiated coverage on Scilex Holding with a new price target

B. Riley Securities initiated coverage on Scilex Holding with a new price target

$SCLX Market Insights

Live Market Insights

$SCLX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Scilex Selling Shareholder Files For Sale Of Up To 3.5M Shares

Scilex Announces Collaboration To Leverage ACEA Therapeutics' R&D Expertise To Support The Expansion Of ZTlido Program In Ex-U.S. And Potentially Provide Additional Access To Patients In Certain Key Markets In Far East Region

Non-Opioid Pain Therapy-Focused Semnur Pharmaceuticals Strikes $2B SPAC Deal For NASDAQ Debut

SEC Form SC 13D/A filed by Scilex Holding Company (Amendment)

SEC Form SC 13D/A filed by Scilex Holding Company (Amendment)

$SCLX Financials

Live finance-specific insights

Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

$SCLX Press Releases

Fastest customizable press release news feed in the world

Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

Recent Analyst Ratings for
$SCLX

$SCLX
Insider Trading

$SCLX
Leadership Updates

$SCLX
SEC Filings

$SCLX
Insider Purchases

$SCLX
Analyst Ratings

$SCLX
Market Insights

$SCLX
Large Ownership Changes

$SCLX
Financials

$SCLX
Press Releases